Clinical Trial Update: A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Feasibility and safety study of a dual specificity CD38 and BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma is being investigated in Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• dual specificity CD38 and BCMA CAR-T cell immunotherapy

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: UNKNOWN